Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◑ V-Series Protocol

V-05Popular · Immune & Inflammation

Calm - Inflammation & Gut

Modulate. Resolve. Restore.

Quick Takeaways

✓Modulates Th1/Th2 immune balance (Thymosin α1)

✓Anti-inflammatory across neural and systemic pathways (VIP)

✓Inhibits NF-κB inflammatory cascade (KPV)

TargetsChronic Inflammation · Immune Resilience

Duration12-week intervention with 6-month maintenance phase

Cohort38 active members

Core Compounds

KPVVIPThymosin α1

Batch 001 Allocation

6 of 20 reserved14 open

Monthly

$335 USD/mo

Founding-Member Savings

Standard (Monthly)$335/mo

6-Month Founding Tier$300/mo

Annual savings$420

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Clinical reasoning per stack

Phase 1 supervision onboarding

V-05 · Copper · Resolution

Composition

Each compound, and what it does

Every component is individually sourced, third-party verified, and dispensed within physician supervision. Tap any compound for its full clinical reference.

▸

Clinical Overview

V-05 Explainer · 90 seconds

Video Coming Soon

Clinical explainer · ~90s · Authored by Vivre Labs Medical Board

◉

Patient Selection

Who This Protocol Is For

A specialized protocol for patients with chronic systemic inflammation that has not resolved with standard interventions. The stack pairs three immunomodulatory peptides addressing distinct pathways - NF-κB inhibition, vasoactive signaling, and T-cell function - to restore inflammatory homeostasis rather than suppress the cascade.

CLINICAL INDICATION: Chronic inflammatory conditions, IBD-adjacent gut inflammation, post-viral inflammatory syndromes, immunosenescence in older adults

Cohort Outcomes · V-05

What members on Calm - Inflammation & Gut report.

n=22 members completing Week 12 of V-05 · Population medians, individual results vary

hs-CRP reduction

-71%

Median, baseline → wk 12

IL-6 reduction

-64%

Pro-inflammatory cytokine

TNF-α reduction

-42%

Chronic inflammatory load

GI symptom score

-58%

For IBD-adjacent indication subset

Member VL-2026-0344 (F, 61) with chronic inflammatory bowel pattern: hs-CRP 8.2 → 1.9, fecal calprotectin normalized over 14 weeks. Discontinued maintenance NSAIDs by week 10 under physician guidance.

Outcomes shown reflect cohort medians from members completing 12 weeks on protocol. Individual outcomes depend on baseline biomarkers, adherence, and physician-directed adjustments. Past cohort performance does not guarantee future results.

◈

Mechanism

How V-05 Works

Anti-inflammatory protocol targeting upstream immune dysregulation. KPV inhibits NF-κB signaling and pro-inflammatory cytokine production; VIP activates VPAC1/VPAC2 receptors with broad systemic immunomodulation; Thymosin α1 supports T-cell maturation and innate immunity. Indicated for chronic systemic inflammation, IBD-adjacent gut inflammation, post-viral inflammatory syndromes, and immunosenescence.

Standard anti-inflammatory therapy suppresses the cascade downstream - NSAIDs block prostaglandins, biologics neutralize cytokines, steroids dampen the entire response. V-05 modulates upstream homeostasis. KPV, VIP, and Thymosin α1 each work through distinct mechanisms but converge on the same outcome: an immune system that responds appropriately rather than persistently.

◇

Formulation

What arrives each month

◇ Multi-Vial Stack

3 separate vials · Separate injections per physician schedule

No pre-blend exists for KPV + VIP + Thymosin α1. Each compound has distinct timing and the physician will sequence administration based on clinical response. Available to partner practices on request - not in the Batch 001 direct catalogue.

What's in the box	Specification	Per month
KPV	10mg vial · 2 vials typical monthly supply	2×
VIP	10mg vial · typical monthly allocation	1×
Thymosin α1	5mg vial · typical monthly allocation	1×

V-05 components tracked individually given inflammatory response variability.

Vial counts shown are operational transparency - what arrives in the monthly allocation box. Administration frequency, per-administration amounts, and reconstitution method are physician-determined at consultation, not on this page.

◇

Components

Core Compounds in V-05

Inflammation

KPV

Tripeptide · 10mg

NF-κB Pathway Inhibition

View Compound →

Neuroimmune Peptide

VIP

Vasoactive Intestinal Peptide · 10mg

VPAC Receptor Agonism

View Compound →

Immunomodulator

Thymosin Alpha-1

Immune Regulator · 10mg

T-Cell Maturation & Activation

View Compound →

∞

Protocol Timeline

Titration Schedule

Wk 1–2

KPV 500mcg/day oral + Thymosin α1 1.6mg 2x/wk

Loading - establish baseline tolerance

Wk 3–8

KPV 500mcg/day + VIP 50mcg 4x/day intranasal + Thymosin α1

Therapeutic phase - week 4 marker checkpoint

Wk 9–12

Maintenance dose per physician

Consolidation - full panel at week 12

Wk 13–24

Cycled maintenance schedule

6-month re-assessment

◐

Clinical Oversight

Monitoring & Safety

Lab Monitoring

hs-CRP, IL-6, TNF-α, fecal calprotectin (when GI-indicated), CD4/CD8 ratio

Contraindications

Active autoimmune flare, acute infection, organ transplant recipients on immunosuppression, ongoing biologic therapy without coordinating prescriber

✚

Patient Bloodwork Guide

Bloodwork for Recovery & Repair Protocols

Tissue repair / anti-inflammatory - BPC-157, TB-500, KPV, Thymosin, V-01, V-05

These protocols support healing of tendon, ligament, gut, and soft tissue, and calm systemic inflammation. Monitoring tracks inflammation coming down and confirms the body is recovering rather than being strained.

Incremental approach. Vivre uses conservative, course-based dosing - often a defined repair window rather than indefinite use. Markers and imaging confirm progress before extending.

Inflammation

hs-CRPA sensitive marker of systemic inflammation - the key “is it calming down” signal.

IL-6An inflammatory messenger; tracked alongside hs-CRP.

ESRA classic inflammation marker for the bigger picture.

Healing confirmation

Imaging (ultrasound)For tendon/ligament work - confirms structural healing, not just how you feel.

Immune markers (CD4/CD8)Where immune modulation (e.g. Thymosin) is part of the protocol.

Overall safety

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

Baselinehs-CRP, IL-6, ESR + imaging of the target area.

Weeks 4 / 8 / 12hs-CRP, IL-6, ESR - track inflammation trend.

Week 12Repeat imaging to confirm structural healing.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊟

Clinical Monitoring Reference

What Your Physician Tracks - and Why

V-05 targets chronic inflammatory dysregulation. The reference set below is what a Vivre physician tracks during supervised use - monitoring practice, not a self-administration guide.

Dosing & Frequency

Physician-supervised protocol with review checkpoints; contraindicated in active autoimmune flare or acute infection (screened first). Dose physician-determined - never self-adjusted.

Biomarker	Why It's Monitored	Baseline	Cadence
hs-CRP	Primary inflammatory efficacy signal	Yes	Wk 4, 8, 12
IL-6	Cytokine-pathway response	Yes	Wk 6, 12
TNF-α	Inflammatory cascade surveillance	Yes	Wk 6, 12
ESR	Adjunct inflammatory marker	Yes	Periodic
CD4/CD8 (where indicated)	Immune-function context	Optional	If clinically indicated
Symptom/tolerability log	Subjective response vs markers	Yes	Ongoing

Monitoring practice shown for education. Allocation and dosing are physician-directed after consultation.

This reference describes physician monitoring practice for educational purposes. It is not a prescription, a dosing instruction, or medical advice. Treatment, dosing, and frequency are determined only by a licensed physician in consultation.

Frequently Asked

Common Questions About V-05

▣

Commonly Paired

Members on V-05 Often Add

Protocol

View protocol →

Protocol

View protocol →

Individual peptide

View compound →

Individual peptide

View compound →

READY TO PROCEED

Start with the Biological Audit

The Audit is complimentary for the Batch 001 cohort. Your physician will review your data, confirm protocol suitability, and initiate the V-05 allocation if appropriate.

$335 USD/mo

V-05 · Monthly